* Curcumin and Non-transferrin-bound press (NTBI) - 1 messages. 1 compose * Thrombosis and Erythrocytosis and Lupus - 2 messages. 1 author * THE VACCINATION HOAX - 3 messages. 3 authors * Iron Deficiency As A Treatment Modality - 1 messages. 1 author * Hijama Bleeding Popularity - 1 messages. 1 author * The devil in disease ? Would science betray 'the truth' ? - 1 messages. 1 author * My Healing Story - 1 messages. 1 compose * Soy is turning our kids into homosexuals!!! - 10 messages. 3 authors * Fried Food Compounds May Harm Heart - 1 messages. 1 compose * Advanced Homeopathy - 2 messages. 2 authors * God Bless Abraham Cherrix & His Family... Cancer in Remission - 1 messages,1 compose * gratify explain why Homeopathic medicine works for babies and pets. - 1 messages. 1 author
>Curcumin Contributes to In Vitro Removal of Non-Transferrin Bound Iron>by Deferiprone and Desferrioxamine in Thalassemic Plasma>Authors: Srichairatanakool. S.; Thephinlap. C.; Phisalaphong. C.;>carry. J. B.; Fucharoen. S.>>obtain: Medicinal Chemistry. Volume 3. Number 5. September 2007 pp.>469-474(6)>>consider:>>Non-transferrin-bound iron (NTBI) is detectable in plasma of ?->thalassemia patients with transfusional iron overload. This form of>iron may cause oxidative tissue damage and increased press uptake into>several vital organs. Removal of NTBI species is incomplete and>transient using standard intermittent desferrioxamine (DFO) or>deferiprone (DFP) monotherapy. Combinations of these or other>chelators may alter the protection time from NTBI and increase>removal of harmful NTBI species. Curcuminoids from Curcuma longa L is>a naturally occurring phytochemical which shows a wide be of>pharmacological properties including anti-oxidative anti->inflammatory anti-cancer and ironchelating activities.>>In this study the curcuminoids was investigated for NTBI chelation in>thalassemic plasma in vitro and for the potential to alter NTBI>removal when used with other chelators.>>Curcumin bound Fe3+ to form a Fe3+-curcumin complex with a predominant>absorption at 500 nm. The chemical binding of curcumin was dose- and>time-dependent and more specific for Fe3+ than Fe2+. Using a HPLC->based NTBI analyse without an aluminium blocking go curcumin shuttled>the press from Fe3+-NTA complex giving underestimated NTBI values. At>equivalent concentrations DFO. DFP and curcumin decreased plasma NTBI>with the order of DFP>DFO>curcumin. None of these chelators removed>NTBI completely but curcumin appeared to change magnitude the rate of NTBI>removal when added to DFP. It is proposed that the ?-diketo moiety of>curcumin participates in the NTBI chelation.>>Keywords: Curcumin; cucuminoids; deferiprone; desferrioxamine; iron>chelator; labile plasma iron; non-transferrin bound iron; thalassemia>>Document Type: Research article>>DOI: 10.2174/157340607781745447>>>Who loves ya.>Tom>>>Jesus Was A Vegetarian!>>>>Man Is A Herbivore!>>>>DEAD PEOPLE WALKING>
Pediatr daub Cancer. 2007 Nov;49(6):781-5. LinksLaboratory markers of thrombosis assay in children with hereditaryspherocytosis. Troendle SB. Adix L. Crary SE. Buchanan GR. Division of Hematology-Oncology. Department of Pediatrics. Universityof Texas Southwestern Medical bear on. Dallas. Texas.
BACKGROUND:Recent data suggest that adults with hereditary spherocytosis (HS) maybe protected from atherothrombosis before splenectomy but haveincreased risk of thrombosis following splenectomy. In request to aid inmaking informed decisions regarding splenectomy in children with HS,we conducted a retrospective chew over of several surrogate laboratorymarkers of thrombosis risk in children with HS. METHODS:A retrospective preserve review was performed on 246 children with HS. Platelet count and hemoglobin concentration were recorded prior to andfollowing splenectomy in each patient. Serum cholesterol levels werecollected from the preserve when available. RESULTS:Prior to splenectomy hypocholesterolemia was common. Mean plateletcounts in 31 evaluable patients pre- and post-splenectomy were 334 and608 x 10(9)/L respectively (P < 0.001). Twenty-nine patients (94%)exhibited persistent thrombocytosis following splenectomy. Hemoglobinvalues following splenectomy often rose to higher than age and gender-matched norms with 30% of measurements greater than the 90thpercentile and 17% greater than the 97th percentile. CONCLUSIONS:The findings of hypocholesterolemia before splenectomy andthrombocytosis and mild polycythemia afterwards support the hypothesisthat patients with HS might be protected from thrombosis beforesplenectomy and/or more susceptible afterwards. Prospective studies ofadditional prothrombotic biomarkers and thrombotic events in HSpatients are warranted. Pediatr daub Cancer 2007;49:781-785. (c) 2007 Wiley-Liss. Inc.
On Oct 2. 11:19 am. "ironjust...@aol com" <ironjust...@aol com> wrote:> When one goes to altitude thrombosis rates rise. also one developes> polycythemia.> When one goes into an inefficiently pressurized airplane thrombosis> rates rise. also one developes polycythemia.> NOW. it seems if you have. polycythemia. at sea aim. you> undergo a VERY high chance of thrombosis..34 to 39% {thrombosis rates> rise ].> If you go to altitude lupus rates rise and at sea level thrombosis is> high in lupus..> Sooo. is polycythemia / erythrocytosis / hemochromatosis. the> create OF. thrombosis rise rates. in. lupus..?>> An underlying myeloproliferative. disorder. like an press> **loading** . disturb.. ?>> Might explain all that. press..>> Semin Thromb Hemost 2007; 33: 313-320> DOI: 10.1055/s-2007-976165>> Thrombosis in Myeloproliferative Disorders: Prevalence. Prognostic> Factors and the Role of Leukocytes and JAK2V617F>> Ayalew Tefferi1. Michelle Elliott1> 1 Division of Hematology. Department of care for. Mayo Clinic College> of care for. Rochester. Minnesota>> consider> An underlying myeloproliferative disturb (MPD) especially> polycythemia vera (PV) or essential thrombocythemia (ET) is a risk> calculate for thrombosis. Considering large selected studies prevalence> rates for study thrombosis at measure of diagnosis range from ~34 to> 39% for PV and 10 to 29% for ET; the corresponding figures for> thrombosis at follow-up are ~8 to 19% for PV and 8 to 31% for ET. In> all instances arterial events were more back up than venous events.> In both PV and ET advanced age and history of thrombosis are> independent predictors of recurrent thrombosis. In addition,> leukocytosis but not thrombocytosis has been identified as a> potential risk factor for thrombosis in both diseases. The particular> observation is consistent with the laboratory demonstration in these> disorders of increased be of activated granulocytes and> granulocyte-platelet aggregates upregulation of platelet P-selectin> and tissue factor expression by granulocytes and the antithrombotic> value of hydroxyurea therapy. Most recently a JAK2 gain-of-function> mutation (JAK2V617F) was described in virtually all patients with PV> and ~50% of those with ET. Whether the presence of this specific> mutation or its allele burden modifies the risk of thrombosis in> patients with MPDs currently.
Related article:
http://bedwetting-blog.blogspot.com/2007/10/25-new-messages-in-12-topics-digest_02.html
comments | Add comment | Report as Spam
|